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a b s t r a c t
In 2008, regadenoson, a selective adenosine2A (A2A) receptor agonist, was approved by the US Fed-
eral and Drug Administration for use as a pharmacologic stress agent in myocardial perfusion studies.
By stimulating A2A receptors in coronary smooth muscle, it can increase coronary blood ﬂow by 2.5-
fold or greater. Previous data showed non-inferiority of regadenoson in detecting reversible myocardial
ischemia, compared to adenosine. Given less serious adverse effects, being better tolerated and easily
administered, regadenoson has beenwidely used for myocardial perfusion imaging. As adenosine recep-
tors havemany sub-types and are located inmulti-organ systems, regadenoson can cause various adverse
effects, including bronchospasm, atrioventricular block, or hypotension. However, adverse effects on the
central nervous system are rarely reported. As adenosine receptors (A1 and A2A receptors) play a major
role in neuron–glial cells interaction, regadenoson can provoke seizure through A2A receptor activation.
Wehereby report a caseof regadenosonassociated-seizure and reviewseizuremechanism. Thismay raise
more concern for a rare serious adverse effect of regadenoson which should be taken into consideration
when selecting cardiac stress modalities.
<Learning objective: Regadenoson can provoke seizure through central A2A receptor activation. This
should be taken into consideration when selecting cardiac stress test modalities, particularly in patients
with known seizure disorder or history of organic brain disease.>
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In 2008, regadenoson, selective adenosine2A (A2A) receptor
gonist, was approved by the US Food and Drug Administra-
ion (FDA) for use as a pharmacologic stress agent in myocardial
erfusion studies. Given less serious adverse effects, being bet-
er tolerated and easily administered, regadenoson has been
idely used for myocardial perfusion imaging. Common adverse
eactions of regadenoson are dyspnea, headache, ﬂushing, chest
iscomfort, dizziness, nausea, andabdominal discomfort.However,
egadenoson-related seizure has only been reported once.
ase reportA 63-year-old male with a history of hypertension, sick sinus
yndrome with pacemaker placed in 2012, and ischemic stroke
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with residual right hemiparesis and expressive aphasia, presented
for a stress test following multiple episodes of intermittent exer-
tional chest pain associated with diaphoresis. Given multiple
atherosclerotic risk factors, the pre-test probability was consid-
ered as moderate risk and he was arranged for regadenoson stress
test. In the stress laboratory, the patientwas injected intravenously
with regadenoson 0.4mg over 15 s per protocol. An estimation of
5min later, the patient developed generalized tonic–clonic seizure
which lasted for 2min. The patient remained confused for 15min
after seizure stopped. At the time, the patient was afebrile with
blood pressure of 115/70mmHg and heart rate of 80/min. There
was no bowel or bladder incontinence or new focal neurolog-
ical deﬁcit observed. The patient denied any history of seizure
disorder or recent head injury. He also denied any fever, chills,
or recent illness. His home medications were aspirin, metopro-
lol, and simvastatin. Upon admission, the patient was alert with
normal orientation. Neurological examinations revealed expres-
sive aphasia, with motor power grade 2/5 and 3/5 at right upper
and lower extremities which were unchanged from baseline. The
rest of the physical examination was unremarkable. The resting
electrocardiography (ECG) showed electronic atrial pacing with no
signiﬁcant ST–Twaveabnormality (Fig. 1). Blood chemistry showed
served.
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aFig. 1. The resting electrocardiogram showed electron
erum sodium of 142mmol/L, potassium of 4mmol/L, calcium
f 9.6mg/L, and glucose of 116mg/dL. Emergent computerized
omography of brain showed cystic encephalomalacia, compatible
ith chronic left middle cerebral artery territory infarct (Fig. 2).
o acute intracranial abnormality was observed. Subsequent elec-
roencephalography (EEG) study did not reveal any epileptiform
ctivity. The patient was admitted to the observation unit for the
ext 24h, during which he remained seizure free. He was subse-
uently discharged home. It was concluded that the seizure was
rovoked by regadenoson.
iscussion
Myocardial perfusion imaging (MPI) is a well-validated, non-
nvasive test for determining the diagnosis, severity, and prognosis
f coronary artery disease.With an inability of the stenotic vessel to
ilate, the discrepancy between normal and diseased myocardium
an be visualized with the myocardial perfusion scan. In general,
ig. 2. Chronic evolution of the leftmiddle cerebral artery infarct territory involving
he left lentiform nucleus and posterior limb of the internal capsule has occurred
ith associated ex vacuo dilatation of the left lateral ventricle. No acute intracranial
bnormality is observed.ial pacing with no signiﬁcant ST–T wave abnormality.
physical exercise is a preferred method of inducing stress. How-
ever, it is not suitable for all patients (e.g. musculoskeletal diseases,
neurological diseases, morbid obesity, or debilitated patients).
Therefore, pharmacological stress tests play a role among these
groups. In the past, adenosine and dipyridamole (inhibiting the cel-
lular uptake of adenosine) were widely used, as they both increase
interstitial adenosine concentration, causing coronary vasodila-
tion through adenosine A2A receptor. However, neither of them is
speciﬁc to A2A receptor on coronary smoothmuscles.With the con-
comitant blocking of A1, A2B, and A3, they can cause various side
effects, such as ﬂushing, chest pain, bronchospasm (A2B, A3), atrio-
ventricular block (A1), and peripheral vasodilation (A2B) [1]. Thus,
the selective A2A receptor agonist, regadenoson, came into interest
after being approved by the FDA in 2008. According to ADVANCE
MPI 1 and 2 trials, regadenoson was non-inferior to adenosine
in detecting reversible myocardial perfusion defects, while being
better tolerated and causing less serious side effects [2,3]. More-
over, regadenoson is more practical and cost-effective, as it does
not require dose adjustment for renal function or body weight
and can be given by a single injection of 0.4mg intravenously. It
can be safely used in chronic obstructive pulmonary disease and
asthma patients, as studies showed no signiﬁcant difference in pul-
monary functionparameters or clinical symptoms after being given
regadenosoncompared toplacebo [4,5]. Regadenoson remains con-
traindicated in second- or third-degree atrioventricular block and
sinus node dysfunction (with an absence of pacemaker) given a
low afﬁnity toward A1 receptor. The report on safety and tolera-
bility of regadenoson from a cross-sectional study in 753 subjects
showed that regadenoson was well tolerated with only one case
reportedof bronchospasmandheart failure exacerbation. The com-
mon adverse symptoms were dyspnea (30%), chest discomfort
(27%), and headache (15%) [6]. In addition, there were no serious
adverse events observed among patients with stage 3–4 chronic
kidney disease, as well as, end-stage renal disease [7,8]. However,
regadenoson provoked seizure in one report [9].
In 1972, Burnstock et al. were the ﬁrst to discover purinergic
neurotransmission, involving release of adenosine tri-phosphate
(ATP) as an efferent neurotransmitter [10]. Later, multiple studies
conﬁrmed that adenosine plays a key role in seizure regulation by
controlling neuron–glial cell interactions, which made adenosine
augmentation a new target of antiepileptic therapy [11]. Adeno-
sine exerts central neuromodulation mainly through A1 and A2A
receptors, given signiﬁcantly lower afﬁnity of A2B and A3 recep-
tors. A1 receptor activation can decrease neuronal transmission
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hrough inhibition of pre-synaptic neurotransmitter release and
tabilization of post-synaptic membrane potential, which leads
o seizure termination. In contrast, A2A receptor activation has
othproconvulsant andanticonvulsant activities, dependingon the
rain location. In animal models, A2A receptor activation at cere-
ral cortex can enhance glutamatergic excitatory, and inhibit the
europrotective activity of the A1 receptor thereby causing cor-
ex and limbic seizures, whereas activation at brainstem inhibits
eizure. Based on this mechanism, the use of a selective adeno-
ine A2A receptor agonist can potentially cause seizure [12,13]. In
ontrast, adenosine and dipyridamole have never been reported
o cause seizure as they also activate A1 receptor which is neu-
oprotective. By excluding other potential causes of seizure, such
s metabolic causes and acute intracerebral pathology, we believe
hat regadenoson caused seizure in our patient. In 2012, Page
t al. reported a case series of regadenoson-associated seizure,
n which most of the patients had known epilepsy. The seizure
volved from partial to secondary generalized seizure. Although
minophylline is used to treat other reactions, its role in treating
eizure remains inconclusive as it was found to prolong seizure in
ne case [9]. We therefore suggest having access to seizure ter-
ination medications (e.g. benzodiazepines) in the area of stress
aboratories.
In conclusion,wehereby report a rare complicationof a common
ardiac stress test, which may raise more concern on stress test
election, particularly in patients with known seizure disorder or
istory of organic brain disease.onﬂict of interest
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